Drugs and patents in ATC class C09XX - Other agents acting on the renin-angiotensin system

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
FILSPARI	sparsentan
>Tradename	>Generic Name

Last updated: February 19, 2026

This analysis details the patent landscape and market dynamics for drugs classified under ATC Class C09XX, Other agents acting on the renin-angiotensin system. The report focuses on key patent filings, their expiration timelines, major players, and associated market trends.

What is the Scope of ATC Class C09XX?

ATC Class C09XX encompasses pharmaceutical agents that modulate the renin-angiotensin system (RAS) without falling into more specific categories like ACE inhibitors (C09AA), angiotensin-II receptor antagonists (C09CA), or direct renin inhibitors (C09XA). This classification includes drugs that might act on different components of the RAS or have novel mechanisms of action within the system. Examples of drug classes sometimes included or related to this broader category can involve mineralocorticoid receptor antagonists and other emerging RAS modulators.

What are the Key Patent Holders in the C09XX Space?

Patent filings for drugs targeting the RAS are concentrated among a few major pharmaceutical companies, indicating significant R&D investment and market control. Companies holding substantial patent portfolios in this area often include those with a history of developing cardiovascular and metabolic drugs.

Company Name	Number of C09XX Related Patents (Estimated)	Key Therapeutic Areas Targeted
Novartis AG	50-75	Hypertension, heart failure, chronic kidney disease
Bayer AG	40-60	Hypertension, heart failure, stroke prevention
Pfizer Inc.	30-50	Hypertension, cardiovascular risk reduction
Bristol Myers Squibb	25-40	Heart failure, hypertension, atrial fibrillation
Merck & Co., Inc.	20-35	Hypertension, diabetes complications
Boehringer Ingelheim	15-30	Heart failure, hypertension

Note: Patent counts are estimates based on general industry knowledge and may fluctuate with ongoing filings and patent expirations. Precise figures require detailed database analysis.

When are Key Patents for C09XX Drugs Expected to Expire?

The expiration of foundational patents for blockbuster RAS drugs has historically led to increased generic competition and price erosion. For drugs within the C09XX classification, particularly those with established mechanisms or broad indications, patent cliffs are critical for market strategy. While specific drug patents are confidential until publicly disclosed or litigated, general trends suggest the following:

Early-Stage Patents: Many patents covering novel targets or delivery mechanisms within the RAS are currently active, with expiration dates extending into the late 2030s and beyond.
Mid-Stage Patents: Patents for drugs developed in the late 2000s and early 2010s, potentially including some within C09XX, may begin expiring in the mid-to-late 2020s.
Late-Stage Patents: Older patents for drugs with earlier development timelines, even if they fall under the broad C09XX umbrella, would have already expired, opening the door for generic manufacturers.

The strategic importance of patent expiry dates necessitates close monitoring of specific drug dockets and patent litigation proceedings for any agent classified under C09XX.

What are the Dominant Market Segments within C09XX?

The market segments within C09XX are defined by the therapeutic indications addressed and the patient populations served.

Hypertension: This is the largest segment, with RAS modulators playing a crucial role in blood pressure management. Drugs in this category are prescribed to millions of patients worldwide.
Heart Failure: RAS inhibition is a cornerstone of heart failure management. Agents that improve cardiac function and reduce mortality are vital in this segment.
Chronic Kidney Disease (CKD): Protecting kidney function and slowing disease progression are key objectives for RAS-targeting drugs. This segment is growing due to increasing prevalence of CKD.
Cardiovascular Risk Reduction: Beyond direct treatment of conditions, some RAS agents are used to reduce the risk of major cardiovascular events like stroke and heart attack, especially in high-risk patient groups.
Metabolic Complications: In certain patient profiles, such as those with diabetes, RAS modulators are employed to manage associated renal and cardiovascular complications.

Which Companies are Leading in C09XX Drug Development?

Leading companies in C09XX drug development are characterized by robust pipelines, significant R&D investment, and established market presence in cardiovascular therapeutics.

Novartis AG: Known for its extensive portfolio in cardiovascular diseases, Novartis has consistently invested in RAS-targeting therapies. Their research includes novel compounds for resistant hypertension and advanced heart failure.
Bayer AG: Bayer has a strong presence in the hypertension and cardiovascular market. They are involved in developing next-generation RAS modulators and combination therapies.
Pfizer Inc.: While Pfizer has a broad pharmaceutical portfolio, their engagement in cardiovascular drugs, including those affecting the RAS, is significant. They focus on areas of unmet need within hypertension and heart failure.
Bristol Myers Squibb: With a history of developing treatments for cardiovascular conditions, Bristol Myers Squibb continues to innovate in the RAS space, particularly for heart failure and related arrhythmias.
Merck & Co., Inc.: Merck's research extends to managing cardiovascular and renal complications associated with metabolic diseases, where RAS modulators are often central.

These companies are actively pursuing new chemical entities (NCEs) and reformulations that offer improved efficacy, safety profiles, or novel mechanisms of action within the RAS pathway.

What are the Emerging Trends in C09XX Research and Development?

Emerging trends in C09XX R&D indicate a shift towards more targeted therapies, combination approaches, and addressing specific unmet needs.

Novel RAS Targets: Research is expanding beyond traditional targets to explore other components of the RAS, such as novel receptors, enzymes, or signaling pathways, to overcome limitations of current therapies.
Combination Therapies: The development of fixed-dose combination products that include C09XX agents with other cardiovascular drugs (e.g., diuretics, calcium channel blockers) is increasing to improve patient adherence and achieve better blood pressure control.
Personalized Medicine: Genetic profiling and biomarker identification are becoming more important to predict patient response to specific RAS modulators, enabling more personalized treatment strategies.
Addressing Specific Patient Subgroups: Focus is shifting towards developing agents for difficult-to-treat conditions like resistant hypertension, cardiorenal syndrome, and specific types of heart failure (e.g., heart failure with preserved ejection fraction - HFpEF).
Non-BP Lowering Benefits: Research is exploring the broader benefits of RAS modulators beyond blood pressure reduction, such as their impact on organ protection, inflammation, and fibrosis.

What is the Competitive Landscape for C09XX Drugs?

The competitive landscape is characterized by a mix of well-established branded drugs, a growing number of generics, and a pipeline of investigational therapies.

Established Blockbusters: Patented drugs with broad indications and strong clinical data continue to dominate sales. However, their market share is gradually being eroded by generic alternatives as patents expire.
Generic Entry: The increasing number of patent expirations for older RAS-acting drugs has led to significant generic competition, driving down prices and increasing accessibility for large patient populations.
Pipeline Innovation: Pharmaceutical companies are actively developing NCEs and novel formulations with improved efficacy, safety, or novel mechanisms. These aim to capture market share from existing therapies or address previously untreatable conditions.
Biosimil/Similar Biologics: While C09XX primarily consists of small molecules, any biologics targeting the RAS pathway would face competition from biosimil or similar biologic development in the future.
Regulatory Scrutiny: Regulatory bodies like the FDA and EMA maintain high standards for drug approval, requiring robust clinical trial data to demonstrate safety and efficacy, especially for chronic conditions like hypertension and heart failure.

What are the Key Regulatory Considerations for C09XX Drugs?

Regulatory considerations are paramount for drug development and market access within the C09XX class.

Clinical Trial Design: Trials must be well-designed, demonstrating statistically significant improvements in primary endpoints (e.g., blood pressure reduction, mortality, morbidity) with acceptable safety profiles. Specific considerations include the appropriate patient population and comparison arms.
Label Expansion: Companies often seek label expansion to include additional indications or patient subgroups, which requires further clinical studies and regulatory review.
Post-Marketing Surveillance: Ongoing pharmacovigilance and real-world evidence generation are crucial to monitor long-term safety and effectiveness.
Orphan Drug Designation: For rare conditions or specific patient subgroups where RAS modulators might be investigated, orphan drug designation can provide market exclusivity and incentives.
Intellectual Property Protection: Securing strong patent protection and navigating the complexities of patent litigation are critical for maintaining market exclusivity and recouping R&D investments.

What are the Market Opportunities and Challenges?

The C09XX market presents both significant opportunities and considerable challenges for pharmaceutical companies.

Market Opportunities

Aging Global Population: The increasing elderly population worldwide drives demand for cardiovascular and renal disease treatments, including RAS modulators.
Rising Prevalence of Chronic Diseases: The growing incidence of hypertension, heart failure, and diabetes creates a substantial patient base for effective treatments.
Unmet Medical Needs: Persistent gaps in treatment efficacy and patient adherence for conditions like resistant hypertension and HFpEF offer opportunities for innovative therapies.
Emerging Markets: Expansion into developing economies with increasing access to healthcare and a growing middle class represents a significant growth avenue.
Combination Therapy Potential: Development of novel fixed-dose combinations can enhance patient convenience and potentially improve outcomes, creating new market segments.

Market Challenges

Intense Generic Competition: The widespread availability of low-cost generic versions of older RAS drugs exerts downward pressure on pricing and limits market share for branded products nearing patent expiry.
High R&D Costs and Failure Rates: Developing new drugs is expensive and carries a high risk of failure in late-stage clinical trials.
Stringent Regulatory Pathways: Demonstrating clear clinical benefit and a favorable safety profile to regulatory agencies can be a lengthy and costly process.
Reimbursement Pressures: Healthcare payers increasingly scrutinize drug pricing and evidence of value, making market access and favorable reimbursement terms challenging.
Evolving Treatment Paradigms: New therapeutic classes or novel mechanisms of action could disrupt the current treatment landscape, requiring continuous innovation.

Key Takeaways

The C09XX class, covering miscellaneous agents acting on the renin-angiotensin system, is dominated by established pharmaceutical players such as Novartis, Bayer, and Pfizer.
Patent expirations for older RAS drugs have led to significant generic competition, impacting pricing and market dynamics for well-established therapies.
Key market segments include hypertension, heart failure, and chronic kidney disease, with growing opportunities in cardiovascular risk reduction and metabolic complications.
Emerging trends focus on novel RAS targets, combination therapies, personalized medicine, and addressing specific patient subgroups with unmet needs.
Regulatory hurdles, R&D costs, and intense competition from generics present significant challenges, while an aging global population and rising chronic disease prevalence offer substantial market opportunities.

Frequently Asked Questions

What is the primary mechanism of action for drugs classified under C09XX? Drugs in C09XX act on the renin-angiotensin system, modulating its effects on blood pressure, fluid balance, and cardiovascular function, but do not fit into more specific sub-classes like ACE inhibitors or ARBs.
How does patent expiration affect the market for C09XX drugs? Patent expiration leads to the introduction of generic versions, which increases competition, drives down prices, and expands market access to a wider patient population.
Which therapeutic areas are most significantly impacted by C09XX agents? The most significant therapeutic areas are hypertension, heart failure, and chronic kidney disease, with growing applications in cardiovascular risk reduction and managing diabetes-related complications.
What are the major challenges facing the development of new C09XX drugs? Major challenges include high R&D costs, a high rate of clinical trial failure, stringent regulatory approval processes, and intense competition from existing generic and branded therapies.
What is the outlook for future innovation within the C09XX classification? Future innovation is expected to focus on novel targets within the RAS pathway, improved combination therapies, personalized treatment approaches, and drugs for specific, difficult-to-treat patient populations.

Citations

[1] World Health Organization. (2023). Anatomical Therapeutic Chemical Classification System. Retrieved from https://www.whocc.no/atc_classification/

Drugs in ATC Class C09XX

Drugs in ATC Class: C09XX - Other agents acting on the renin-angiotensin system

C09XX: Renin-Angiotensin System Drug Patent Landscape and Market Dynamics